Pasar al contenido principal

C-RAF, UN MEDIADOR CLAVE EN TUMORES INDUCIDOS POR EL ONCOGEN K-RAS: ESTRATEGIAS TERAPEUTICAS

RTI2018-094664-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.

  • de-la-Puente-Ovejero, Laura
  • Fernández-Rodríguez, Ana
  • Francoz, Sarah
  • Aizpurua, Gonzalo
  • Lomba-Riego, Lucía
  • Drosten, Matthias
  • Guerra, Carmen
  • Musteanu, Mónica
  • Barbacid, Mariano
  • García-Alonso, Sara
KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive candidate for targeted protein degradation. However, the therapeutic impact and safety of co-targeting RAF1 with related kinases remain unclear.
Repisalud
Publicación Artículo científico (JournalArticle)

Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation.

  • García-Alonso, Sara
  • Mesa, Pablo
  • Ovejero, Laura de la Puente
  • Aizpurua, Gonzalo
  • Lechuga, Carmen G
  • Zarzuela, Eduardo
  • Santiveri, Clara M
  • Sanclemente, Manuel
  • Muñoz, Javier
  • Musteanu, Mónica
  • Campos-Olivas, Ramón
  • Martínez-Torrecuadrada, Jorge
  • Barbacid, Mariano
  • Montoya, Guillermo
RAF kinases are RAS-activated enzymes that initiate signaling through the MAPK cascade to control cellular proliferation, differentiation, and survival. Here, we describe the structure of the full-length RAF1 protein in complex with HSP90 and CDC37 obtained by cryoelectron microscopy. The reconstruction reveals a RAF1 kinase with an unfolded N-lobe separated from its C-lobe. The hydrophobic core of the N-lobe is trapped in the HSP90 dimer, while CDC37 wraps around the chaperone and interacts with the N- and C-lobes of the kinase. The structure indicates how CDC37 can discriminate between the different members of the RAF family. Our structural analysis also reveals that the folded RAF1 assembles with 14-3-3 dimers, suggesting that after folding RAF1 follows a similar activation as B-RAF. Finally, disruption of the interaction between CDC37 and the DFG segment of RAF1 unveils potential vulnerabilities in attempting the pharmacological degradation of RAF1 for therapeutic purposes.
Repisalud
Publicación Artículo científico (JournalArticle)

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.

  • Fernández-García, Fernando
  • Fernández-Rodríguez, Ana
  • Fustero-Torre, Coral
  • Piñeiro-Yáñez, Elena
  • Wang, Haiyun
  • Lechuga, Carmen G
  • Callejas, Sergio
  • Álvarez, Rebeca
  • López-García, Alejandra
  • Esteban-Burgos, Laura
  • Salmón, Marina
  • San Román, Marta
  • Guerra, Carmen
  • Ambrogio, Chiara
  • Drosten, Matthias
  • Santamaría, David
  • Al-Shahrour, Fatima
  • Dopazo, Ana
  • Barbacid, Mariano
  • Musteanu, Mónica
Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the high intratumoral heterogeneity characteristic of these tumors. In this study, we have attempted to identify those functional alterations that result from KRAS oncoprotein expression during the earliest stages of tumor development. Such functional changes are likely to be maintained during the entire process of tumor progression regardless of additional co-occurring mutations. Single-cell RNA sequencing analysis of murine alveolar type 2 cells expressing a resident oncogene revealed impairment of the type I interferon pathway, a feature maintained throughout tumor progression. This alteration was also present in advanced murine and human tumors harboring additional mutations in the p53 or LKB1 tumor suppressors. Restoration of type I interferon (IFN) signaling by IFN-β or constitutive active stimulator of interferon genes (STING) expression had a profound influence on the tumor microenvironment, switching them from immunologically "cold" to immunologically "hot" tumors. Therefore, enhancement of the type I IFN pathway predisposes KRAS mutant lung tumors to immunotherapy treatments, regardless of co-occurring mutations in p53 or LKB1.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Combined inhibition of FOSL-1 and YAP using siRNA-lipoplexes reduces the growth of pancreatic tumor

  • Diego González, Lara
  • Fernández Carrera, Andrea
  • Igea Fernandez, Ana
  • Martínez Pérez, Amparo
  • Real Oliveira, M. Elisabete C. D.
  • Gomes, Andreia C.
  • Guerra, Carmen
  • Barbacid, Mariano
  • González Fernández, Maria Africa
  • Simón Vázquez, Rosana
Pancreatic cancer evades most of the current therapies and there is an urgent need for new treatments that could efficiently eliminate this aggressive tumor, such as the blocking of routes driving cell proliferation. In this work, we propose the use of small interfering RNA (siRNA) to inhibit the combined expression of FOSL-1 and YAP, two signaling proteins related with tumor cell proliferation and survival. To improve the efficacy of cell transfection, DODAB:MO (1:2) liposomes were used as siRNA nanocarriers, forming a complex denominated siRNA-lipoplexes. Liposomes and lipoplexes (carrying two siRNA for each targeted protein, or the combination of four siRNAs) were physico-chemically and biologically characterized. They showed very good biocompatibility and stability. The efficient targeting of FOSL-1 and YAP expression at both mRNA and protein levels was first proved in vitro using mouse pancreatic tumoral cell lines (KRASG12V and p53 knockout), followed by in vivo studies using subcutaneous allografts on mice. The peri-tumoral injection of lipoplexes lead to a significant decrease in the tumor growth in both Athymic Nude-Foxn1nu and C57BL/6 mice, mainly in those receiving the combination of four siRNAs, targeting both YAP and FOSL-1. These results open a new perspective to overcome the fast tumor progression in pancreatic cancer., Xunta de Galicia | Ref. ED431C 2020/02, Xunta de Galicia | Ref. ED431G2019/06, Ministerio de Ciencia, Innovación y Universidades | Ref. RTI2018-094664-B-I00, Ministerio de Economía, Industria y Competitividad | Ref. BIO2017-84974-R
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

  • Paniagua, Guillem
  • Jacob, Harrys K.C.
  • Brehey, Oksana
  • García-Alonso, Sara
  • Lechuga, Carmen G.
  • Pons, Tirso
  • Musteanu, Mónica
  • Guerra, Carmen
  • Drosten, Matthias
  • Barbacid, Mariano
The kinase suppressor of rat sarcoma (RAS) proteins (KSR1 and KSR2) have long been considered as scaffolding proteins required for optimal mitogen-activated protein kinase (MAPK) pathway signalling. However, recent evidence suggests that they play a more complex role within this pathway. Here, we demonstrate that ectopic expression of KSR1 or KSR2 is sufficient to activate the MAPK pathway and to induce cell proliferation in the absence of RAS proteins. In contrast, the ectopic expression of KSR proteins is not sufficient to induce cell proliferation in the absence of either rapidly accelerated fibrosarcoma (RAF) or MAPK-ERK kinase proteins, indicating that they act upstream of RAF. Indeed, KSR1 requires dimerization with at least one member of the RAF family to stimulate proliferation, an event that results in the translocation of the heterodimerized RAF protein to the cell membrane. Mutations in the conserved aspartic acid–phenylalanine–glycine motif of KSR1 that affect ATP binding impair the induction of cell proliferation. We also show that increased expression levels of KSR1 decrease the responsiveness to the KRASG12C inhibitor sotorasib in human cancer cell lines, thus suggesting that increased levels of expression of KSR may make tumour cells less dependent on KRAS oncogenic signalling., This work was supported by grants from the European Research Council (ERC-AG/695566, THERACAN), the Spanish Ministry of Science, Innovation and Universities (RTI2018-094664-B-I00 and RTC2017-6576-1), the Autonomous Community of Madrid (B2017/BMD-3884 iLUNG-CM), the CRIS Cancer Foundation and the Asociación Española contra el Cáncer (AECC) (GC166173694BARB). MB is a recipient of an Endowed Chair from the AXA Research Fund. GP has been supported by a fellowship from the Programa de Atracción de Talento of the Autonomous Community of Madrid. SGA is a recipient of a postdoctoral fellowship from the AECC. OB is a recipient of a fellowship from the Formación de Personal Investigador (FPI) program of the Spanish Ministry of Science, Innovation and Universities.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

  • Salmón, Marina
  • Álvarez-Díaz, Ruth
  • Fustero-Torre, Coral
  • Brehey, Oksana
  • Lechuga, Carmen G.
  • Sanclemente, Manuel
  • Fernández-García, Fernando
  • López-García, Alejandra
  • Martín-Guijarro, María Carmen
  • Rodríguez-Perales, Sandra
  • Bousquet-Mur, Emily
  • Morales-Cacho, Lucía
  • Mulero, Francisca
  • Al-Shahrour, Fátima
  • Martínez, Lola
  • Domínguez, Orlando
  • Caleiras, Eduardo
  • Ortega, Sagrario
  • Guerra, Carmen
  • Musteanu, Mónica
  • Drosten, Matthias
  • Barbacid, Mariano
KRASG12C inhibitors have revolutionized the clinical management of patients with KRASG12C-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically engineered mice to compare the therapeutic efficacy and the emergence of tumor resistance between genetic ablation of mutant Kras expression and pharmacological inhibition of oncogenic KRAS activity. Whereas Kras ablation induces massive tumor regression and prevents the appearance of resistant cells in vivo, treatment of KrasG12C/Trp53-driven lung adenocarcinomas with sotorasib, a selective KRASG12C inhibitor, caused a limited antitumor response similar to that observed in the clinic, including the rapid onset of resistance. Unlike in human tumors, we did not observe mutations in components of the RAS-signaling pathways. Instead, sotorasib-resistant tumors displayed amplification of the mutant Kras allele and activation of xenobiotic metabolism pathways, suggesting that reduction of the on-target activity of KRASG12C inhibitors is the main mechanism responsible for the onset of resistance. In sum, our results suggest that resistance to KRAS inhibitors could be prevented by achieving a more robust inhibition of KRAS signaling mimicking the results obtained upon Kras ablation., This work was supported by grants from the European Research Council (ERC-GA 695566, THERACAN); the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033) (grant RTC2017-6576-1), cofunded by ERDF “A way of making Europe”; the Autonomous Community of Madrid (B2017/BMD-3884 iLung-CM), cofunded by FSE and ERDF “A way of making Europe”; the CRIS Cancer Foundation, the Scientific Foundation of the Spanish Association Against Cancer (GC166173694BARB); an ERA PerMed grant, funded by the Instituto de Salud Carlos III (AC20/00114), the Scientific Foundation of the Spanish Association Against Cancer (PERME20707BARB) and the European Union’s Horizon 2020 program (779282) to MB; and the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant RTI2018-094664-B-I00), cofunded by ERDF “A way of making Europe” to MM and MB. Additional funding included grants from the Spanish National Research and Development Plan, Instituto de Salud Carlos III, ERDF “A way of making Europe” (PI20/01837 and DTS19/00111); the Scientific Foundation of the Spanish Association Against Cancer (LABAE20049RODR) to SRP; the Instituto de Salud Carlos III (PI19/00514), cofunded by ERDF “A way of making Europe” to CG; the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (grant PID2020-116705RB-I00); and the Scientific Foundation of the Spanish Association Against Cancer (LABAE211678DROS) to MD. MB is a recipient of an endowed chair from the AXA Research Fund. M Salmón was supported by a predoctoral contract “Severo Ochoa” (BES-2016-079096) from the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación. OB is a recipient of a fellowship from the Formación de Personal Investigador (FPI) program of the Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación. FFG was supported by a Formación de Profesorado Universitario (FPU) fellowship from the Ministerio de Universidades., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

  • Fernández-García, Fernando
  • Fernández-Rodríguez, Ana
  • Fustero-Torre, Coral
  • Piñeiro-Yáñez, Elena
  • Wang, Haiyun
  • Lechuga, Carmen G.
  • Callejas, Sergio
  • Álvarez, Rebeca
  • López-García, Alejandra
  • Esteban-Burgos, Laura
  • Salmón, Marina
  • Román, Marta San
  • Guerra, Carmen
  • Ambrogio, Chiara
  • Drosten, Matthias
  • Santamaria, David
  • Al-Shahrour, Fátima
  • Dopazo, Ana
  • Barbacid, Mariano
  • Musteanu, Mónica
Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the high intratumoral heterogeneity characteristic of these tumors. In this study, we have attempted to identify those functional alterations that result from KRAS oncoprotein expression during the earliest stages of tumor development. Such functional changes are likely to be maintained during the entire process of tumor progression regardless of additional co-occurring mutations. Single-cell RNA sequencing analysis of murine alveolar type 2 cells expressing a resident Kras oncogene revealed impairment of the type I interferon pathway, a feature maintained throughout tumor progression. This alteration was also present in advanced murine and human tumors harboring additional mutations in the p53 or LKB1 tumor suppressors. Restoration of type I interferon (IFN) signaling by IFN-β or constitutive active stimulator of interferon genes (STING) expression had a profound influence on the tumor microenvironment, switching them from immunologically “cold” to immunologically “hot” tumors. Therefore, enhancement of the type I IFN pathway predisposes KRAS mutant lung tumors to immunotherapy treatments, regardless of co-occurring mutations in p53 or LKB1., This work was supported by grants from the European Research Council (ERC-AG/695566, THERACAN) to M.B. and grants from the Spanish Ministry of Science, Innovation and Universities cofounded by the European Regional Development Fund “A way of making Europe”: RTI2018-094664-B-I00 to M.B. and M.M. and PID2021-122797OB-I00 to M.M. M.B. is a recipient of an Endowed Chair from the AXA Research Fund. M.M. is recipient of a “Ramón y Cajal” fellowship from the Spanish Ministry of Science, Innovation and Universities. F.F.-G. and A.F.-R. were supported by a Formación de Profesorado Universitario fellowship from the Spanish Ministry of Science, Innovation and Universities., Peer reviewed